Video: Roberto Soto, MD, discusses using PET imaging with Amyvid for Alzheimer’s evaluation, including reimbursement, training, and benefits of the new test.
The FDA in April approved the radioactive diagnostic agent florbetapir, name brand Amyvid, for use with PET imaging for the evaluation of Alzheimer’s disease.
As the first FDA-approved agent for brain imaging of amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer’s and other causes, Amyvid binds to amyloid plaques, considered a key player in Alzheimer’s disease, and is detected in PET scans.
A scan showing few or no amyloid plaques would mean a reduced likelihood the impairment is due to Alzheimer’s and can help rule out the disease. A positive scan showing moderate to frequent amyloid plaques is present in people with Alzheimer’s, as well as patient with other neurologic conditions and normal aging.
Last year, the FDA expressed concerns about radiologists’ ability to consistently read the scans, so Amyvid developer Ely Lilly developed a reader training program.
As the number of sites using Amyvid continues to grow, Diagnostic Imaging visited Precision Imaging in Rockville, Md., which has been using the agent for a few years as part of clinical trials.
In this video, Roberto Soto, MD, founder and medical officer of Precision Imaging, discusses the reimbursement challenges, the training provided, and the utility of the new imaging test.
CT Study: AI Algorithm Comparable to Radiologists in Differentiating Small Renal Masses
May 14th 2024An emerging deep learning algorithm had a lower AUC and sensitivity than urological radiologists for differentiating between small renal masses on computed tomography (CT) scans but had a 21 percent higher sensitivity rate than non-urological radiologists, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Finds High Concordance Between AI and Radiologists for Cervical Spine Fractures on CT
May 6th 2024Researchers found a 98.3 percent concordance between attending radiology reports and AI assessments for possible cervical spine fractures on CT, according to new research presented at the 2024 ARRS Annual Meeting.